MSCs can not only directly restrain proliferation of the effector B cells [11–13, 36] but also induce differentiation of the CD19+CD5+ B cell subset of patients with graft versus host disease, which secretes IL-10, thus being recognized as Bregs [18]. Here, CD19 is linked to graft versus host disease.